Erythropoeitin in Sickle Cell Anaemia: A Review
Obeagu Emmanuel Ifeanyi
Abstract
Paleness is a typical condition in principally sick patients and results in a high prerequisite for blood transfusions related with poor results. Anaemia is the primary symptom which is ABSTRACT Sickle Cell Anaemia (SCA) is one of the most prevalent monogenic disorders. The formation of polymerized haemoglobin leading to erythrocyte rigidity and appearance of characteristic sickle-shaped Red blood Cells (RBCs) resulting in vascular occlusion and haemolysis is central to the molecular pathogenesis of the disease. Normally, Erythropoeitin (EPO) level vary inversely with haematocrit if the kidney is not adversely damaged. Hypoxia stimulates Erythropoeitin (EPO) release, which, in turn, stimulates bone marrow erythrocyte production. High blood levels of RBC, hemoglobin, haematocrit, or oxygen suppress the release of (EPO).